JPRN-UMIN000012119已完成未知
Clinical evaluation of Asparagine Synthetase (ASNS) Level in Leukemia/ Lymphoma Cells by Monoclonal Antibodies - ASNS in Leukemia/Lymphoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with concomitant active cancer 2) Patients with active viral hepatitis or HBs-Ag positive 3) Patients with known CNS involvement of the lymphoma 4) Patients with previous serious allergy to any of the drugs given 5) Patients with abnormalities in cardiac function or clinically significant heart disease such as acute myocardial infarction or unstable angina within 6 months prior to the start of study treatment, heart failure NYHA class III or IV, uncontrolled hypertension or poor compliance of antihypertensive treatment, uncontrolled arrhythmias 6) Patients with serious or uncontrolled medical condition such as uncontrolled diabetes, uncontrolled active infection, significant cerebrovascular disease or poorly controlled psychiatric disease 7) Patients unable to give written informed consent 8) Others: Inappropriate patients determined by a principal investigator or sub-investigators
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial - - Efficacy and safety of recombinant asparaginase in infants with previously untreated AAcute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in the bone marrow leads to suppression of normal haematopoiesis as well as disseminated infiltration of organs and release of blasts into periphal blood.MedDRA version: 9.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaEUCTR2008-006300-27-DEmedac Gesellschaft für klinische Spezialpräparate mbH12
进行中（未招募）
不适用
Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial - - Efficacy and safety of recombinant asparaginase in infants with previously untreated AEUCTR2008-006300-27-NLmedac Gesellschaft für klinische Spezialpräparate mbH12
已完成
2 期
Efficacy and safety of recombinant asparaginase in infants ( < 1 year) with previously untreated acute lymphoblastic leukemia, a phase II clinical trialacute lymphoblastic leukemia in infants10024324NL-OMON33689Medac6
已完成
不适用
Pharmacokinetics of asparaginase in patients with acute lymphoblastic leukemia: prospective observational study.acute lymphoblastic leukemia (ALL)JPRN-UMIN000040630Japan Children's Cancer Study Group(JCCG)110
已完成
不适用
A pilot study of L-asparaginase monotherapy for Epstein-Barr virus positive T or NK cell lymphoproliferative disease (Chronic active Epstein-Barr virus infection)Epstein-Barr virus positive T or NK cell lymphoproliferative disease (Chronic active Epstein-Barr virus infection)JPRN-UMIN000003498Tokyo Medical and Dental University School of Medicine, Department of Hematology5